As part of the deal, Veristat will provide strategic statistical consulting and biometrics services, including study design, statistical analysis and data presentation, for a number of new cancer programs carried out by Karyopharm.
The company’s cancer programs include acute myeloid leukemia, diffuse large B-cell lymphoma, Richter’s transformation, glioblastoma, gynecological malignancies, prostate cancer and squamous cell carcinomas.
Karyopharm founder, president and chief scientific officer Sharon Shacham said the company required a strategic partner and teammate for its programs who understands the therapeutic and regulatory aspects of its multiple trials with its novel nuclear export inhibitor Selinexor.
"We believe that we have found an important partner for Karyopharm given Veristat’s depth of experience in oncology and with novel therapeutics," Shacham said.
Veristat president John Balser said the company is happy to be chosen by Karyopharm to assist them in the development of their novel therapeutics.
"We are pleased to bring our experience, scientific expertise and enthusiasm to the many programs Karyopharm has underway," Balser said.
Karyopharm is focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.